top of page
Browse by category
Search
Gastric pouch resizing for recurrent weight gain promotes weight stabilisation in well-selected patients
Gastric pouch resizing (GPR) for recurrent weight gain after primary RYGB is a safe procedure promoting weight stabilisation or even mild...
COVID-19 pandemic: Bariatric surgery patients showed an increase in the percentage of weight regain
Two years after the start of the COVID-19 pandemic, bariatric surgery patients showed an increase in the percentage of weight regain and...
Semaglutide and liraglutide may reduce alcohol consumption in individuals with AUD
A joint study by the University of Eastern Finland and Karolinska Institutet in Sweden has found that the GLP-1 agonists semaglutide and...
NK2R burns energy and lowers appetite without the nausea and vomiting
Scientists at the University of Copenhagen have discovered a new weight loss drug target, neurokinin 2 receptor (NK2R), that reduces...
Adults with pre-diabetes and obesity or overweight treated with tirzepatide had sustained weight loss and nearly 99% remained diabetes-free at 176 weeks
Results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide,...
Helix model can predict 12-month weight loss response of semaglutide in diverse populations
Helix has unveiled new clinical research at the American Society of Human Genetics (ASHG) 2024 Annual Meeting, featuring a novel...
Browse by tag
bottom of page